SCHEMBL2080394

SCHEMBL2080394

CCOC(=O)c1c(O)c2c([nH]c1=O)CCN(C(=O)OCC)CC2

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.70
USP2 O75604 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.44
PABPC1 P11940 1/20 0.44
ATM Q13315 1/20 0.44
KDM4E B2RXH2 4/20 0.43
PKM P14618 2/20 0.43
MAPT P10636 3/20 0.42
KDM5A P29375 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
ALDH1A1 P00352 3/20 0.41
POLB P06746 1/20 0.40
TSHR P16473 2/20 0.40
ADORA1 P30542 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 2/20 0.39
BLM P54132 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2078683 0.91 LMNA (0.62) LMNAUSP2SMN1; SMN2PABPC1ATM
SCHEMBL2080285 0.86 LMNA (0.52) LMNASMN1; SMN2PABPC1ATMKDM4E
SCHEMBL1062502 0.83 LMNA (1.00) LMNAUSP2SMN1; SMN2KDM4EPKM
SCHEMBL17629552 0.79 LMNA (0.68) LMNAUSP2SMN1; SMN2KDM4EPKM
SCHEMBL17629578 0.76 LMNA (0.68) LMNAUSP2SMN1; SMN2KDM4EPKM
SCHEMBL2077232 0.74 LMNA (0.51) LMNASMN1; SMN2PABPC1ATMKDM4E
SCHEMBL17629492 0.74 LMNA (0.65) LMNAUSP2SMN1; SMN2KDM4EPKM
SCHEMBL2078909 0.73 MAPT (0.54) LMNASMN1; SMN2PABPC1ATMKDM4E
SCHEMBL2079812 0.73 ADORA1 (0.48) LMNASMN1; SMN2ATMKDM4EMAPT
SCHEMBL17629573 0.72 LMNA (0.60) LMNAUSP2SMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897595-B2 Pyridoazepine derivatives FOREST LABORATORIES HOLDINGS LIMITED (BM) 2011-03-01 US claimed
US-20070281918-A1 PYRIDOAZEPINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2007-12-06 US claimed
US-7897595-B2 Pyridoazepine derivatives FOREST LABORATORIES HOLDINGS LIMITED (BM) 2011-03-01 US disclosed
WO-2007140213-A1 PYRIDOAZEPINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2007-12-06 WO disclosed
US-20070281918-A1 PYRIDOAZEPINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281918-A1 PYRIDOAZEPINE DERIVATIVES HTR2C, HTR5A, HTR2A LMNA 1039/4885USP2 3252/4885SMN1; SMN2 2821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.